750 reports of this reaction
2.7% of all LOPINAVIR AND RITONAVIR reports
#6 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #6 most commonly reported adverse reaction for LOPINAVIR AND RITONAVIR, manufactured by AbbVie Inc.. There are 750 FDA adverse event reports linking LOPINAVIR AND RITONAVIR to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 2.7% of all 28,252 adverse event reports for this drug.
Patients taking LOPINAVIR AND RITONAVIR who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for LOPINAVIR AND RITONAVIR, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for LOPINAVIR AND RITONAVIR:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 750 FDA reports for LOPINAVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 2.7% of all adverse event reports for LOPINAVIR AND RITONAVIR, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking LOPINAVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.